Search

Your search keyword '"Virchis, Andres E."' showing total 13 results
Start Over Author "Virchis, Andres E."
13 results on '"Virchis, Andres E."'

1. RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature

Author

Chapman, Michael A., Sive, Jonathan, Ambrose, John, Roddie, Claire, Counsell, Nicholas, Lach, Anna, Abbasian, Mahnaz, Popat, Rakesh, Cavenagh, Jamie D., Oakervee, Heather, Streetly, Matthew J., Schey, Stephen, Koh, Mickey, Willis, Fenella, Virchis, Andres E., Crowe, Josephine, Quinn, Michael F., Cook, Gordon, Crawley, Charles R., Pratt, Guy, Cook, Mark, Braganza, Nivette, Adedayo, Toyin, Smith, Paul, Clifton-Hadley, Laura, Owen, Roger G., Sonneveld, Pieter, Keats, Jonathan J., Herrero, Javier, and Yong, Kwee

Published
2018
Full Text
View/download PDF

3. A Phase I Study Evaluating the Safety and Persistence of Allorestricted WT1-TCR Gene Modified Autologous T Cells in Patients with High-Risk Myeloid Malignancies Unsuitable for Allogeneic Stem Cell Transplantation

Author

Morris, Emma C, primary, Tendeiro-Rego, Rita, additional, Richardson, Rachel, additional, Fox, Thomas A, additional, Sillito, Francesca, additional, Holler, Angelika, additional, Thomas, Sharyn, additional, Xue, Shao-An, additional, Martínez-Dávila, Irma Alicia, additional, Nicholson, Emma, additional, Ahmadi, Mandana, additional, King, Judith, additional, Kottaridis, Panagiotis, additional, Chakraverty, Ronjon, additional, Thomson, Kirsty, additional, Robinson, Stephen, additional, Virchis, Andres E., additional, Khwaja, Asim, additional, Quaye, Michelle, additional, Zhan, Hong, additional, Qasim, Waseem, additional, Himoudi, Nourredine, additional, Barry, Jacqueline, additional, Mount, Natalie, additional, Gaskell, Terri, additional, Sharpe, Michaela, additional, Inman, Shannon M, additional, Gunter, Kurt C., additional, and Stauss, Hans, additional

Published
2019
Full Text
View/download PDF

4. Efficacy and Safety of Carfilzomib at 56mg/m2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study

Author

Yong, Kwee, primary, Popat, Rakesh, primary, Wilson, William, primary, Pang, Gavin, primary, Jenner, Richard, primary, De Tute, Ruth M, primary, Ramasamy, Karthik, primary, Streetly, Matthew, primary, Cavenagh, Jamie, primary, Sive, Jonathan, primary, Chapman, Michael, primary, Bygrave, Ceri, primary, Phillips, Beth, primary, Chavda, Selina J, primary, Virchis, Andres E., primary, Benjamin, Reuben, primary, Arnott, Sarah, primary, Willis, Fenella, primary, Hassan, Sandra, primary, Moore, Sally, primary, Clifton-Hadley, Laura, primary, and Owen, Roger G, primary

Published
2019
Full Text
View/download PDF

6. Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)

Author

Popat, Rakesh, De Tute, Ruth Mary, Counsell, Nicholas, De-Silva, Dunnya, Phillips, Beth, Cavenagh, James D, Adedayo, Toyin, Braganza, Nivette, Roddie, Claire, Streetly, Mathew, Schey, Stephen, Koh, Mickey, Crowe, Josephine, Quinn, Michael F., D'Sa, Shirley, Virchis, Andres E., Cook, Gordon, Crawley, Charles R, Pratt, Guy, Cook, Mark, Smith, Paul, Clifton-Hadley, Laura, Rabin, Neil, Owen, Roger G, and Yong, Kwee

Published
2017
Full Text
View/download PDF

7. A Seven Gene Signature to Distinguish Bortezomib- and Lenalidomide-Responsive Myeloma: Rnaseq from the Padimac Study

Author

Chapman, Michael, Sive, Jonathan, Ambrose, John, Roddie, Claire, Counsell, Nicholas, Smith, Paul, Braganza, Nivette, Adedayo, Toyin, Popat, Rakesh, Cavenagh, James D, Streetly, Matthew J., Owen, Roger G., Schey, Stephen, Koh, Mickey, Crowe, Josephine, Quinn, Michael F., D'Sa, Shirley, Virchis, Andres E., Cook, Gordon, Crawley, Charles R, Pratt, Guy, Cook, Mark, Clifton-Hadley, Laura, Herrero, Javier, and Yong, Kwee

Published
2017
Full Text
View/download PDF

9. Autologous Stem Cell Transplantation Using BEAM Conditioning Is Highly Effective in Patients with Follicular Lymphoma Regardless of Prior Rituximab Exposure

Author

Kothari, Jaimal, primary, Ljubic, Antonia, additional, Peggs, Karl S, additional, Thomson, Kirsty, additional, Morris, Emma, additional, Virchis, Andres E., additional, Lambert, Jonathan, additional, Goldstone, Anthony H, additional, Linch, David C, additional, and Ardeshna, Kirit M, additional

Published
2011
Full Text
View/download PDF

11. Efficacy and Safety of Carfilzomib at 56mg/m2with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study

Author

Yong, Kwee, Popat, Rakesh, Wilson, William, Pang, Gavin, Jenner, Richard, De Tute, Ruth M, Ramasamy, Karthik, Streetly, Matthew, Cavenagh, Jamie, Sive, Jonathan, Chapman, Michael, Bygrave, Ceri, Phillips, Beth, Chavda, Selina J, Virchis, Andres E., Benjamin, Reuben, Arnott, Sarah, Willis, Fenella, Hassan, Sandra, Moore, Sally, Clifton-Hadley, Laura, and Owen, Roger G

Abstract

Introduction:Carfilzomib (20/36mg/m2) triplets with Lenalidomide-Dexamethasone (KRd), or Cyclophosphamide-Dexamethasone (KCd) are safe and effective in patients with newly diagnosed multiple myeloma(NDMM). The higher dose of 56mg/m2is effective as a doublet with Dexamethasone in the relapsed setting, but there is limited data on this dose in triplet combinations in the frontline setting.

Published
2019
Full Text
View/download PDF

13. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro.

Author

Ganeshaguru K, Wickremasinghe RG, Jones DT, Gordon M, Hart SM, Virchis AE, Prentice HG, Hoffbrand AV, Man A, Champain K, Csermak K, and Mehta AB

Subjects
2-Chloroadenosine pharmacology, ATP Binding Cassette Transporter, Subfamily B, Member 1 metabolism, Aged, Aged, 80 and over, Apoptosis drug effects, B-Lymphocytes drug effects, B-Lymphocytes enzymology, Calcium Channel Blockers pharmacology, Chlorambucil pharmacology, Deoxyadenosines pharmacology, Drug Resistance, Multiple, Drug Resistance, Neoplasm, Drug Screening Assays, Antitumor, Female, Humans, In Situ Nick-End Labeling, Male, Middle Aged, Palatine Tonsil cytology, Tumor Cells, Cultured drug effects, Tumor Cells, Cultured enzymology, Verapamil pharmacology, Vidarabine analogs & derivatives, Vidarabine pharmacology, 2-Chloroadenosine analogs & derivatives, Antineoplastic Agents pharmacology, Enzyme Inhibitors pharmacology, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Neoplasm Proteins antagonists & inhibitors, Protein Kinase C antagonists & inhibitors, Staurosporine analogs & derivatives, Staurosporine pharmacology
Abstract

Background and Objectives: The staurosporine derivative PKC412 (CGP41251) is a more selective inhibitor of the conventional isoforms of protein kinase C (PKC) than is the parent compound. In addition to its growth inhibitory properties, PKC412 reverses the efflux function of the multidrug resistance (MDR)-1 gene product, P-glycoprotein (P-gp)., Design and Methods: The in vitro actions of PKC412 were investigated in peripheral blood lymphocytes (PBL) from 4 normal volunteers, B-cell isolates from 3 normal tonsils and 31 patients with B-cell chronic lymphocytic leukemia (B-CLL). Following incubation with PKC412 for 2 days, the viability of B-CLL cells was decreased relative to that of controls (63+/-23% at 1 micromole/L; 52+/-30% at 10 micromole/L; n=20). Normal PBL were significantly more resistant to the drug (91+/-5% viable cells at 1 micromole/L; 73+/-18% at 10 micromole/L; n=4). Thirteen of the B-CLL patients were treated with oral PKC412 in a phase II trial., Results: PKC activity in malignant cells from these patients showed a reduction post-treatment of 25-96% of their respective pre-treatment levels. Morphologic analysis, as well as in situ assay for DNA strand breaks (TUNEL assay) showed that B-CLL cells were killed by an apoptotic mechanism. In B-CLL cells the mean IC50, for PKC412, as measured by the reduction of 3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), was 2.1 micromol/L in 16 samples in which the IC50 were below the maximum concentration of PKC412 used for the assay. In tonsillar B-cells, the mean IC50 was 11 micromol/L whereas PBL cells were resistant. Four of eight and 1/3 B-CLL samples that were resistant to chlorambucil and fludarabine, respectively, were sensitive to PKC412. In 15/31 B-CLL samples a dose-dependent reversal of P-gp-mediated drug efflux by PKC412 was observed. A statistically significant correlation (p<0.001) was observed between P-gp protein expression as measured by FACScan analysis and the reversal of efflux activity by either PKC412 or verapamil. PKC412 increased the sensitivity of B-CLL cells to 2'-chlorodeoxyadenosine and chlorambucil., Interpretation and Conclusions: This study establishes the in vitro cytotoxic and multidrug resistance (MDR) modulatory properties of PKC412 towards malignant cells from B-CLL patients. The direct antitumor activity combined with the potential for P-gp modulation make PKC412 an attractive drug for the treatment of malignancies expressing the MDR phenotype, or in combination with conventional drugs.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results